Growth factors and myometrium: Biological effects in uterine fibroid and possible clinical implications

Human Reproduction Update

Volumn 17, Issue 6, 2011, Pages 772-790

  Ciarmela, Pasquapina ^a   Islam, Md Soriful ^a   Reis, Fernando M ^b,c   Gray, Peter C ^d   Bloise, Enrrico ^e   Petraglia, Felice ^e   Vale, Wylie ^d   Castellucci, Mario ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c National Institute of Hormones and Women's Health   (Brazil)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e Obstetrics and Reproductive Medicine ^*  (Italy)

Author keywords

Growth factors; Leiomyoma; Myometrium; Steroid hormones

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACTIVIN; ACTIVIN A; CYCLINE; EPIDERMAL GROWTH FACTOR; ESTROGEN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GONADORELIN AGONIST; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MIFEPRISTONE; MYOSTATIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROGESTERONE; RALOXIFENE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; BONE DENSITY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; ESTROGEN DEFICIENCY; EXTRACELLULAR MATRIX; HUMAN; HYSTERECTOMY; MYOMECTOMY; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA;

FEMALE; GONADAL STEROID HORMONES; GROWTH SUBSTANCES; HUMANS; LEIOMYOMA; MODELS, BIOLOGICAL; MYOMETRIUM; PREGNANCY; SIGNAL TRANSDUCTION; UTERINE NEOPLASMS;

EID: 80054712751     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmr031     Document Type: Article

References (187)

1. Amirouche A, Durieux AC, Banzet S, Koulmann N, Bonnefoy R, Mouret C, Bigard X, Peinnequin A, Freyssenet D. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009;150:286-294.
2. Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 1997;3:685-691.
3. Andersen J, Barbieri RL. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig 1995;2:663-672.
4. Andersen J, Grine E, Eng CL, Zhao K, Barbieri RL, Chumas JC, Brink PR. Expression of connexin-43 in human myometrium and leiomyoma. Am J Obstet Gynecol 1993; 169:1266-1276.
5. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000;73:1006-1011.
6. Arici A, Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am J Obstet Gynecol 2003;188:76-83.
7. Arita S, Kikkawa F, Kajiyama H, Shibata K, Kawai M, Mizuno K, Nagasaka T, Ino K, Nomura S. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Int J Gynecol Cancer 2005;15:329-336.
8. Barbarisi A, Petillo O, Di Lieto A, Melone MA, Margarucci S, Cannas M, Peluso G. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol 2001; 186:414-424.
9. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990;63:515-524.
10. Betsholtz C, Johnsson A, Heldin CH, Westermark B, Lind P, Urdea MS, Eddy R, Shows TB, Philpott K, Mellor AL. et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature 1986;320:695-699.
11. Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells. Endocrinology 2001; 142:1065-1072.
12. Boehm KD, Daimon M, Gorodeski IG, Sheean LA, Utian WH, Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 1990;27:93-101.
13. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 1997; 76:245-255.
14. Burroughs KD, Fuchs-Young R, Davis B, Walker CL. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol Reprod 2000; 63:1322-1330.
15. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-7712.
16. Catherino WH, Malik M, Driggers P, Chappel S, Segars J, Davis J. Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium. J Steroid Biochem Mol Biol 2010;122:279-286.
17. Cesen-Cummings K, Houston KD, Copland JA, Moorman VJ, Walker CL, Davis BJ. Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling. J Soc Gynecol Investig 2003;10:11-20.
18. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 2010; 28:180-203.
19. Chegini N, Zhao Y, Williams RS, Flanders KC. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 1994; 135:439-449.
20. Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 2002;8:1071-1078.
21. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol 2003; 209:9-16.
22. Ciarmela P, Wiater E, Vale W. Activin-A in myometrium: characterization of the actions on myometrial cells. Endocrinology 2008;149:2506-2516.
23. Ciarmela P, Wiater E, Smith SM, Vale W. Presence, actions, and regulation of myostatin in rat uterus and myometrial cells. Endocrinology 2009;150:906-914.
24. Ciarmela P, Bloise E, Gray PC, Carrarelli P, Islam MS, De Pascalis F, Severi FM, Vale W, Castellucci M, Petraglia F. Activin-A and myostatin response and steroid regulation in human myometrium: disruption of Their signalling in uterine fibroid. J Clin Endocrinol Metab 2011;96:755-765.
25. Ciccodicola A, Dono R, Obici S, Simeone A, Zollo M, Persico MG. Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. Embo J 1989;8:1987-1991.
26. Condon J, Yin S, Mayhew B, Word RA, Wright WE, Shay JW, Rainey WE. Telomerase immortalization of human myometrial cells. Biol Reprod 2002; 67:506-514.
27. Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, Wilson E, Saraf KA, Liu W, McCampbell AS. et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009;69:6171-6178.
28. Dalla-Favera R, Gallo RC, Giallongo A, Croce CM. Chromosomal localization of the human homolog (c-sis) of the simian sarcoma virus onc gene. Science 1982; 218:686-688.
29. De Falco M, Staibano S, D'Armiento FP, Mascolo M, Salvatore G, Busiello A, Carbone IF, Pollio F, Di Lieto A. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig 2006; 13:297-303.
30. Di X, Yu L, Moore AB, Castro L, Zheng X, Hermon T, Dixon D. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum Reprod 2008;23:1873-1883.
31. Di Lieto A, De Rosa G, De Falco M, Iannotti F, Staibano S, Pollio F, Scaramellino M, Salvatore G. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment. Hum Pathol 2002;33:220-224.
32. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/ extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 2004;89:5549-5557.
33. Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000;108(Suppl 5):795-802.
34. Dodin S, Lemay A, Maheux R, Dumont M, Turcot-Lemay L. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991;77:410-415.
35. Dou Q, Zhao Y, Tarnuzzer RW, Rong H, Williams RS, Schultz GS, Chegini N. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 1996;81:3222-3230.
36. Draper LB, Chong H, Wang E, Woodruff TK. The uterine myometrium is a target for increased levels of activin A during pregnancy. Endocrinology 1997; 138:3042-3046.
37. Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol 2002;175:41-54.
38. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. Embo J 1997;16:1268-1278.
39. Emoto M, Iwasaki H, Ishiguro M, Kikuchi M, Horiuchi S, Saito T, Tsukamoto N, Kawarabayashi T. Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 1999; 30:1232-1241.
40. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009; 24:1870-1879.
41. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688.
42. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-234.
43. Fayed YM, Tsibris JC, Langenberg PW, Robertson AL Jr. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest 1989;60:30-37.
44. Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet 2010;109:121-124.
45. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 1994;5:353-377.
46. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037-1054.
47. Frishman GN, Jurema MW. Myomas and myomectomy. J Minim Invasive Gynecol 2005;12:443-456; quiz 457-448.
48. Gao Z, Matsuo H, Wang Y, Nakago S, Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2001;86:5593-5599.
49. Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 2001;101:691-695.
50. Giudice LC, Irwin JC, Dsupin BA, Pannier EM, Jin IH, Vu TH, Hoffman AR. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 1993;8:1796-1806.
51. Gloudemans T, Prinsen I, Van Unnik JA, Lips CJ, Den Otter W, Sussenbach JS. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res 1990;50:6689-6695.
52. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114.
53. Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA 2003; 100:5193-5198.
54. Gray PC, Shani G, Aung K, Kelber J, Vale W. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol 2006; 26:9268-9278.
55. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J. et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997;17:71-74.
56. Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, Bicknell R, Rees MC. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000; 6:2808-2814.
57. Harrison CA, Gray PC, Fischer WH, Donaldson C, Choe S, Vale W. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors. J Biol Chem 2004;279:28036-28044.
58. Harrison CA, Gray PC, Vale WW, Robertson DM. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005; 16:73-78.
59. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995; 80:1853-1858.
60. Hayashi K, Carpenter KD, Gray CA, Spencer TE. The activin-follistatin system in the neonatal ovine uterus. Biol Reprod 2003;69:843-850.
61. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 2002;398:284-290.
62. Hermon TL, Moore AB, Yu L, Kissling GE, Castora FJ, Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch 2008; 453:557-569.
63. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-939.
64. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002; 277:40735-40741.
65. Hill GD, Moore AB, Kissling GE, Flagler ND, Ney E, Cline JM, Dixon D. Effects of hormonally active agents on steroid hormone receptor expression and cell proliferation in the myometrium of ovariectomized macaques. Toxicol Pathol 2011;39:508-515.
66. Hofmann GE, Rao CV, Barrows GH, Schultz GS, Sanfilippo JS. Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab 1984;58:880-884.
67. Hong T, Shimada Y, Uchida S, Itami A, Li Z, Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001;8:141-148.
68. Hwu YM, Li SH, Lee RK, Tsai YH, Yeh TS, Lin SY. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril 2008;89:468-471.
69. Hyder SM, Huang JC, Nawaz Z, Boettger-Tong H, Makela S, Chiappetta C, Stancel GM. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 2000;108(Suppl 5):785-790.
70. Iwamoto I, Fujino T, Higashi Y, Tsuji T, Nakamura N, Komokata T, Douchi T. Metastasis of uterine leiomyosarcoma to the pancreas. J Obstet Gynaecol Res 2005;31:531-534.
71. Jaffer S, Shynlova O, Lye S. Mammalian target of rapamycin is activated in associationwith myometrial proliferation during pregnancy. Endocrinology 2009;150:4672-4680.
72. Johansson B. Different types of smooth muscle hypertrophy. Hypertension 1984; 6:III64-III68.
73. Jones RL, Kaitu'u-Lino TJ, Nie G, Sanchez-Partida LG, Findlay JK, Salamonsen LA. Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse. Reproduction 2006; 132:799-810.
74. Joseph DS, Malik M, Nurudeen S, Catherino WH. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 2010;93:1500-1508.
75. Kambadur R, Sharma M, Smith TP, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997; 7:910-916.
76. Kelber JA, Shani G, Booker EC, Vale WW, Gray PC. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal. J Biol Chem 2008;283:4490-4500.
77. Korupolu RV, Muenster U, Read JD, Vale W, Fischer WH. Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin. J Biol Chem 2008;283:3782-3790.
78. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res 2005;3:679-684.
79. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI, Walker CL. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007;13:3087-3099.
80. Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002;22:8184-8198.
81. Lebrun JJ, Takabe K, Chen Y, Vale W. Roles of pathway-specific and inhibitory Smads in activin receptor signaling. Mol Endocrinol 1999;13:15-23.
82. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001;86:913-920.
83. Lei J, Jiang A, Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1998; 1443:400-406.
84. Levens E, Luo X, Ding L, Williams RS, Chegini N. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling. Mol Hum Reprod 2005;11:489-494.
85. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W, Nieman LK. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-1136.
86. Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther 2006; 5:28-33.
87. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005;146:1097-1118.
88. Luo X, Ding L, Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod 2006; 12:245-256.
89. Luo X, Yin P, Coon VJ, Cheng YH, Wiehle RD, Bulun SE. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 2010;93:2668-2673.
90. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med 2010;28:169-179.
91. Mangrulkar RS, Ono M, Ishikawa M, Takashima S, Klagsbrun M, Nowak RA. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 1995;53:636-646.
92. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am 2006;33:59-67.
93. Maruo T, Matsuo H, Shimomura Y, Kurachi O, Gao Z, Nakago S, Yamada T, Chen W, Wang J. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 2003;68:817-824.
94. Massague J. Epidermal growth factor-like transforming growth factor. I. Isolation, chemical characterization, and potentiation by other transforming factors from feline sarcoma virus-transformed rat cells. J Biol Chem 1983;258:13606-13613.
95. Massague J, Attisano L, Wrana JL. The TGF-beta family and its composite receptors. Trends Cell Biol 1994;4:172-178.
96. Matsuo H, Kurachi O, Shimomura Y, Samoto T, Maruo T. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 1999;57(Suppl 2):49-58.
97. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007;26:3113-3121.
98. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94:12457-12461.
99. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
100. Mesquita FS, Dyer SN, Heinrich DA, Bulun SE, Marsh EE, Nowak RA. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod 2010;82:341-351.
101. Monga M, Ku CY, Dodge K, Sanborn BM. Oxytocin-stimulated responses in a pregnant human immortalized myometrial cell line. Biol Reprod 1996;55:427-432.
102. Moore AB, He H, Yoshida A, Rico PJ, Haseman JK, Dixon D. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice. Exp Toxicol Pathol 2000;52:195-200.
103. Moore AB, Castro L, Yu L, Zheng X, Di X, Sifre MI, Kissling GE, Newbold RR, Bortner CD, Dixon D. Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration. Hum Reprod 2007;22:2623-2631.
104. Moore AB, Yu L, Swartz CD, Zheng X, Wang L, Castro L, Kissling GE, Walmer DK, Robboy SJ, Dixon D. Human uterine leiomyoma-derived fibroblasts stimulate uterine leiomyoma cell proliferation and collagen type I production, and activate RTKs and TGF beta receptor signaling in coculture. Cell Commun Signal 2010;8:10.
105. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007;3:e79.
106. Muenster U, Harrison CA, Donaldson C, Vale W, Fischer WH. An activin-A/C chimera exhibits activin and myostatin antagonistic properties. J Biol Chem 2005;280:36626-36632.
107. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010;19:77-91.
108. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH. et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389:631-635.
109. Newbold RR, Moore AB, Dixon D. Characterization of uterine leiomyomas in CD-1 mice following developmental exposure to diethylstilbestrol (DES). Toxicol Pathol 2002;30:611-616.
110. Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology 2009;150:2436-2445.
111. Norian JM, Malik M, Parker CY, Joseph D, Leppert PC, Segars JH, Catherino WH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci 2009;16:1153-1164.
112. Nowak RA. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ Health Perspect 2000;108(Suppl 5):849-853.
113. Ohara N. Action of progesterone receptor modulators on uterine leiomyomas. Clin Exp Obstet Gynecol 2008;35:165-166.
114. Ohara N, Morikawa A, Chen W, Wang J, DeManno DA, Chwalisz K, Maruo T. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 2007;14:20-27.
115. Olive DL, Pritts EA. Fibroids and reproduction. Semin Reprod Med 2010; 28:218-227.
116. Olufowobi O, Sharif K, Papaionnou S, Neelakantan D, Mohammed H, Afnan M. Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital. J Obstet Gynaecol 2004; 24:434-440.
117. Osman B, Doller A, Akool el S, Holdener M, Hintermann E, Pfeilschifter J, Eberhardt W. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell Signal 2009;21:1806-1817.
118. Palman C, Bowen-Pope DF, Brooks JJ. Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 1992; 66:108-115.
119. Pekonen F, Nyman T, Rutanen EM. Differential expression of keratinocyte growth factor and its receptor in the human uterus. Mol Cell Endocrinol 1993; 95:43-49.
120. Peng L, Wen Y, Han Y, Wei A, Shi G, Mizuguchi M, Lee P, Hernando E, Mittal K, Wei JJ. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil Steril 2009; 91:2664-2675.
121. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272:7151-7158.
122. Pusztai L, Lewis CE, Lorenzen J, McGee JO. Growth factors: regulation of normal and neoplastic growth. J Pathol 1993;169:191-201.
123. Rauk PN, Surti U, Roberts JM, Michalopoulos G. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol 1995;173:571-577.
124. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003;23:7230-7242.
125. Rider V, Carlone DL, Foster RT. Oestrogen and progesterone control basic fibroblast growth factor mRNA in the rat uterus. J Endocrinol 1997;154:75-84.
126. Rossi MJ, Chegini N, Masterson BJ. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 1992;130:1716-1727.
127. Samathanam CA, Adesanya OO, Zhou J, Wang J, Bondy CA. Fibroblast growth factors 1 and 2 in the primate uterus. Biol Reprod 1998;59:491-496.
128. Sanci M, Dikis C, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem 2011;113:317-325.
129. Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:655-676.
130. Schneider-Kolsky M, Manuelpillai U, Gargett C, Wallace EM. Activin betaA-subunit and activin receptors in human myometrium at term and during labour. BJOG 2001;108:869-874.
131. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-2688.
132. Sharp HT. Assessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomata. Obstet Gynecol 2006;108:990-1003.
133. Shen MM. Nodal signaling: developmental roles and regulation. Development 2007; 134:1023-1034.
134. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998;83:2192-2198.
135. Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R, Hartzstark Z, Ben-Bassat H. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 2004;19:1957-1967.
136. Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 2007;87:127-135.
137. Shynlova O, Oldenhof A, Dorogin A, Xu Q, Mu J, Nashman N, Lye SJ. Myometrial apoptosis: activation of the caspase cascade in the pregnant rat myometrium at midgestation. Biol Reprod 2006;74:839-849.
138. Shynlova O, Tsui P, Dorogin A, Langille BL, Lye SJ. The expression of transforming growth factor beta in pregnant rat myometrium is hormone and stretch dependent. Reproduction 2007a;134:503-511.
139. Shynlova O, Tsui P, Dorogin A, Langille BL, Lye SJ. Insulin-like growth factors and their binding proteins define specific phases of myometrial differentiation during pregnancy in the rat. Biol Reprod 2007b;76:571-578.
140. Shynlova O, Tsui P, Jaffer S, Lye SJ. Integration of endocrine and mechanical signals in the regulation of myometrial functions during pregnancy and labour. Eur J Obstet Gynecol Reprod Biol 2009;144(Suppl 1):S2-10.
141. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 2002;78:1-12.
142. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-324.
143. Stewart EA. Uterine fibroids. Lancet 2001;357:293-298.
144. Strawn EY Jr, Novy MJ, Burry KA, Bethea CL. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol 1995;172:1837-1843; discussion 1843-1834.
145. Strizzi L, Bianco C, Hirota M, Watanabe K, Mancino M, Hamada S, Raafat A, Lawson S, Ebert AD, D'Antonio A. et al. Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. J Pathol 2007;211:36-44.
146. Suo G, Jiang Y, Cowan B, Wang JY. Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol Reprod 2009;81:749-758.
147. Swartz CD, Afshari CA, Yu L, Hall KE, Dixon D. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod 2005;11:441-450.
148. Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res 2000;26:325-331.
149. Tam JP, Marquardt H, Rosberger DF, Wong TW, Todaro GJ. Synthesis of biologically active rat transforming growth factor I. Nature 1984;309:376-378.
150. Tang XM, Dou Q, Zhao Y, McLean F, Davis J, Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod 1997;3:233-240.
151. Taniguchi Y, Morita I, Kubota T, Murota S, Aso T. Human uterine myometrial smooth muscle cell proliferation and vascular endothelial growth-factor production in response to platelet-derived growth factor. J Endocrinol 2001; 169:79-86.
152. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, Kambadur R. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000;275:40235-40243.
153. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947-11954.
154. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:157-166.
155. Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem 2000;275:40788-40796.
156. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008;55:11-21.
157. Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S. Activins and inhibins and their signaling. Ann N Y Acad Sci 2004;1038:142-147.
158. van der Poel HG. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. J Urol 2004;172:1333-1337.
159. Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS, Den Otter W. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer 1997; 75:1631-1640.
160. Vollenhoven BJ, Herington AC, Healy DL. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J Clin Endocrinol Metab 1993;76:1106-1110.
161. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308:1589-1592.
162. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004;104:393-406.
163. Wang XN, Das SK, Damm D, Klagsbrun M, Abraham JA, Dey SK. Differential regulation of heparin-binding epidermal growth factor-like growth factor in the adult ovariectomized mouse uterus by progesterone and estrogen. Endocrinology 1994;135:1264-1271.
164. Wang J, Ohara N, Takekida S, Xu Q, Maruo T. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells. Hum Reprod 2005;20:1456-1465.
165. Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, DeManno DA, Chwalisz K, Maruo T. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod2006; 21:1869-1877.
166. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, Chwalisz K. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696-1704.
167. Wolanska M, Bankowski E. An accumulation of insulin-like growth factor I (IGF-I) in human myometrium and uterine leiomyomas in various stages of tumour growth. Eur Cytokine Netw 2004;15:359-363.
168. Wolanska M, Bankowski E. Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth. Biochimie 2006; 88:141-146.
169. Wolanska M, Bankowski E. Transforming growth factor beta and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth. Eur J Obstet Gynecol Reprod Biol 2007;130:238-244.
170. Wolanska M, Bankowska-Guszczyn E, Jaworski S. [Fibroblast growth factor gene expression in uterine leiomyomas]. Ginekol Pol 2008;79:555-559.
171. Wu X, Blanck A, Olovsson M, Moller B, Favini R, Lindblom B. Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. Acta Obstet Gynecol Scand 2000;79:397-404.
172. Wu X, Blanck A, Olovsson M, Moller B, Lindblom B. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment. Acta Obstet Gynecol Scand 2001;80:497-504.
173. Wu X, Wang H, Englund K, Blanck A, Lindblom B, Sahlin L. Expression of progesterone receptors A and B and insulin-like growth factor-I in human myometrium and fibroids after treatment with a gonadotropin-releasing hormone analogue. Fertil Steril 2002;78:985-993.
174. Xu J, Luo X, Chegini N. Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 2003;88:1350-1361.
175. Yamada T, Nakago S, Kurachi O, Wang J, Takekida S, Matsuo H, Maruo T. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod 2004;19:815-821.
176. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
177. Yeh J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril 1991;56:997-1000.
178. Yen-Ping Ho J, Man WC, Wen Y, Polan ML, Shih-Chu Ho E, Chen B. Transforming growth interacting factor expression in leiomyoma compared with myometrium. Fertil Steril 2010;94:1078-1083.
179. Ying Z, Weiyuan Z. Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B. Gynecol Endocrinol 2009; 25:520-523.
180. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, Sasaki H, Morikawa A, Maruo T. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28:260-273.
181. Yu H, Berkel H. Insulin-like growth factors and cancer. J La State Med Soc 1999; 151:218-223.
182. Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, Di X, Lucas S, Robboy SJ, Dixon D. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 2008;14:264-275.
183. Yu L, Moore AB, Dixon D. Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma. Semin Reprod Med 2010;28:250-259.
184. Zhang Z, Funk C, Roy D, Glasser S, Mulholland J. Heparin-binding epidermal growth factor-like growth factor is differentially regulated by progesterone and estradiol in rat uterine epithelial and stromal cells. Endocrinology 1994; 134:1089-1094.
185. Zhao Y, Zhang W, Wang S. The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. Gynecol Endocrinol 2008;24:549-554.
186. Zhu X, Topouzis S, Liang LF, Stotish RL. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine 2004;26:262-272.
187. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001;8:161-173.